Alzheimer's and aging biomarkers
Plasma and CSF biomarker assays, tau-related targets, NfL, GFAP, and validation planning.
Experience built around complex translational problems
VexisBio is most useful when a program is scientifically promising but not yet packaged in a way U.S. stakeholders can evaluate.
Our project rhythm
The value is not only running an experiment. The value is deciding which experiment matters, generating credible evidence, and explaining the result in the right context.
Question
Define the biological, technical, and commercial question.
Strategy
Select assay, reagent, and validation paths.
Evidence
Generate fit-for-purpose experimental data.
Interpretation
Assess performance, limitations, and risk.
Package
Build a U.S.-facing technical narrative.
Focus areas
ELISA and antibody development
Assay pairing, capture/detection optimization, reagent qualification, and lot consistency.
ELISA-qPCR concepts
Antibody-oligo conjugation and qPCR-readable immunoassay feasibility.
circRNA support
RNA expression, detection, biomarker support, and mechanism-oriented assay planning.
Diagnostic assay feasibility
From proof-of-concept to U.S.-ready development packages.
To-USA translation
Scientific positioning, documentation, and partner-facing clarity.